- Home
- OPAD vs ALXO Comparison
OPAD vs ALXO Comparison
Compare OPAD & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- ALXO
- Stock Information
- Founded
- OPAD 2015
- ALXO 2015
- Country
- OPAD United States
- ALXO United States
- Employees
- OPAD N/A
- ALXO N/A
- Industry
- OPAD Real Estate
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- ALXO Health Care
- Exchange
- OPAD Nasdaq
- ALXO Nasdaq
- Market Cap
- OPAD 70.1M
- ALXO 76.5M
- IPO Year
- OPAD N/A
- ALXO 2020
- Fundamental
- Price
- OPAD $1.71
- ALXO $0.97
- Analyst Decision
- OPAD Hold
- ALXO Strong Buy
- Analyst Count
- OPAD 5
- ALXO 6
- Target Price
- OPAD $3.25
- ALXO $4.14
- AVG Volume (30 Days)
- OPAD 85.3K
- ALXO 1.3M
- Earning Date
- OPAD 05-05-2025
- ALXO 03-06-2025
- Dividend Yield
- OPAD N/A
- ALXO N/A
- EPS Growth
- OPAD N/A
- ALXO N/A
- EPS
- OPAD N/A
- ALXO N/A
- Revenue
- OPAD $918,819,000.00
- ALXO N/A
- Revenue This Year
- OPAD $8.29
- ALXO N/A
- Revenue Next Year
- OPAD $33.17
- ALXO N/A
- P/E Ratio
- OPAD N/A
- ALXO N/A
- Revenue Growth
- OPAD N/A
- ALXO N/A
- 52 Week Low
- OPAD $1.64
- ALXO $0.89
- 52 Week High
- OPAD $8.79
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- OPAD 34.34
- ALXO 41.74
- Support Level
- OPAD $1.64
- ALXO $0.89
- Resistance Level
- OPAD $2.09
- ALXO $1.50
- Average True Range (ATR)
- OPAD 0.20
- ALXO 0.13
- MACD
- OPAD -0.01
- ALXO 0.01
- Stochastic Oscillator
- OPAD 8.28
- ALXO 13.10
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.